DelveInsight’s, “Hepatitis A Pipeline Insight, 2022,” report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in Hepatitis A pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Key takeaways from the Hepatitis A Pipeline Report

• DelveInsight’s Hepatitis A Pipeline report depicts a robust space with 3+ active players working to develop 3+ pipeline therapies for Hepatitis A treatment.
• The leading Hepatitis A Companies such as Boryung Pharmaceutical, Cadila Healthcare, Indian Immunologicals, Biological E Limited, and others are developing potential drug candidates to improve the Hepatitis A treatment scenario.
• The promising Hepatitis A therapies in the pipeline included such as Havrix Inj, MP-424 (Telaprevir), Avaxim 80U, Havrix 720 Junior, Recombinant Hepatitis E Vaccine (Escherichia Coli), and others
• The companies and academics are working to assess challenges and seek opportunities that could influence Hepatitis A R&D. The therapies under development are focused on novel approaches to treat/improve Hepatitis A.

 

Get an overview of the pipeline landscape @ Hepatitis A Pipeline Outlook

 

Hepatitis A Overview

Hepatitis A is caused by a virus resulting from an acute inflammation of the liver; it is the most common form of all viral hepatitis. It is encountered frequently in the most disadvantaged geographical regions. Generally, this inflammation is a result of a lack of safe water, and poor sanitation and hygiene. It is encountered frequently in urban areas but the incidence rates differ according to geographical regions and socio-economic levels. Despite progress in sanitation and hygiene, hepatitis A occurs sporadically and in epidemics worldwide, with a tendency for cyclic recurrences. The disease can lead to significant economic and social consequences in communities. The impact on food establishments identified with the virus, and local productivity in general, can be substantial.

 

Latest Breakthroughs and Developments in the Hepatitis A Treatment Landscape

• Inactivated hepatitis A vaccine is being developed by Indian Immunologicals for prevention of Hepatitis A infection. The vaccine is currently in Phase II/III stage of clinical trial evaluation.
• Biological E Limited is developing an Inactivated Hepatitis A Vaccine. The vaccine is currently in Phase III stage of clinical trial evaluation.

 

Hepatitis A Emerging Drugs

• Inactivated Hepatitis A Vaccine: Biological E Limited
• Hepatitis A vaccine inactivated: Indian Immunologicals

 

Hepatitis A Pipeline Therapeutics Analysis

There are approx. 3+ key companies which are developing the therapies for Hepatitis A. The companies which have their Hepatitis A drug candidates in the most advanced stage, i.e. phase III include, Biological E Limited.

 

For further information, refer to the detailed report @ Hepatitis A Emerging Therapies

 

Scope of the Hepatitis A Pipeline Report

• Coverage- Global
• Hepatitis A Companies- Boryung Pharmaceutical, Cadila Healthcare, Indian Immunologicals, Biological E Limited, and others
• Hepatitis A Therapies- Havrix Inj, MP-424 (Telaprevir), Avaxim 80U, Havrix 720 Junior, Recombinant Hepatitis E Vaccine (Escherichia Coli), and others
• Hepatitis A Therapeutic Assessment by Product Type
• Hepatitis A Therapeutic Assessment by Stage and Product Type
• Hepatitis A Therapeutic Assessment by Route of Administration
• Hepatitis A Therapeutic Assessment by Stage and Route of Administration
• Hepatitis A Therapeutic Assessment by Molecule Type
• Hepatitis A Therapeutic Assessment by Stage and Molecule Type
• Hepatitis A companies’ collaborations, Licensing, Acquisition -Deal Value Trends
• Hepatitis A – Market Drivers and Barriers

 

Table of Content

1. Introduction
2. Executive Summary
3. Hepatitis A: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Hepatitis A – DelveInsight’s Analytical Perspective
7. Late Stage Products (Phase III)
8. Inactivated Hepatitis A Vaccine: Biological E Limited
9. Mid-Stage Products (Phase II/III)
10. HAV 1001: Cadila Healthcare
11. Early Stage Products (Phase I)
12. Inactive Products
13. Hepatitis A Key Companies
14. Hepatitis A Key Products
15. Hepatitis A- Unmet Needs
16. Hepatitis A- Market Drivers and Barriers
17. Hepatitis A- Future Perspectives and Conclusion
18. Hepatitis A Analyst Views
19. Hepatitis A Key Companies
20. Appendix

 

Got Queries? Reach out for more information on the Hepatitis A Pipeline Report- Hepatitis A Pipeline Therapeutic Assessment

 

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/